Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Mitsuya Website

Hiroaki Mitsuya, M.D., Ph.D.

Selected Publications

1)  Yedidi RS, Garimella H, Aoki M, Aoki H, Desai DV, Chang SB, Davis DA, Fyvie WS, Kaufman JD, Smith DW, Das D, Wingfield PT, Maeda K, Ghosh AK, Mitsuya H.
Conserved hydrogen-bonding network of P2 bis-tetrahydrofuran containing HIV-1 protease inhibitors (PI) with protease active site amino acid-backbone aid in their activity against PI-resistant HIV.
Antimicrob. Agents Chemother. [Epub ahead of print], 2014.
[Journal]
2)  Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H.
Delayed emergence of HIV-1 variants resistant to 4"-ethynyl-2-fluoro-2"-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Antivir. Ther. (Lond.). 19: 179-89, 2014.
[Journal]
3)  Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H.
EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.
J. Invest. Dermatol. 134: 1158-61, 2014.
[Journal]
4)  Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.
IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Eur. J. Haematol. [Epub ahead of print], 2014.
[Journal]
5)  Muftuoglu Y, Sohl CD, Mislak AC, Mitsuya H, Sarafianos SG, Anderson KS.
Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4"-ethynyl-2-fluoro-2"-deoxyadenosine (EFdA) using pre-steady-state kinetics.
Antiviral Res. 106C: 1-4, 2014.
[Journal]
6)  Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S.
Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial.
Intern. Med. 52: 735-44, 2013.
[Journal]
7)  Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S.
Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
Free Radic. Biol. Med. 65: 778-88, 2013.
[Journal]
8)  Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.
Effects of substitutions at the 4" and 2 positions on the bioactivity of 4"-ethynyl-2-fluoro-2"-deoxyadenosine.
Antimicrob. Agents Chemother. 57: 6254-64, 2013.
[Journal]
9)  Hachiya A, Reeve AB, Marchand B, Michailidis E, Ong YT, Kirby KA, Leslie MD, Oka S, Kodama EN, Rohan LC, Mitsuya H, Parniak MA, Sarafianos SG.
Evaluation of combinations of 4'-ethynyl-2-fluoro-2'-deoxyadenosine with clinically used antiretroviral drugs.
Antimicrob. Agents Chemother. [Epub ahead of print], 2013.
[Journal]
10)  Salcedo Gómez PM, Amano M, Yashchuk S, Mizuno A, Das D, Ghosh AK, Mitsuya H.
GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Antimicrob. Agents Chemother. 57: 6110-21, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/8/2014.